Beyond 1L EGFRm mNSCLC Management: Today’s Challenges, Tomorrow’s Approach

UCLA Health
A

HERTHENA-Lung01 Study: Patritumab Deruxtecan as a HER3 Target in EGFRm Advanced NSCLC

By UCLA Health FEATURING Aaron Lisberg
By UCLA Health FEATURING Aaron Lisberg
166 views
May 9, 2024
Comments 0
Login to view comments. Click here to Login
13:17

ADCs in Lung Cancer: A Transformative Therapeutic Class?

Joshua Reuss

293 views
21:24

ADCs and Bispecific Inhibitors in NSCLC

Chul Kim

632 views
16:17

Non-TKI-Based Strategies for EGFR Common Mutations

Timothy Burns

328 views
20:28

mNSCLC Updates: 1L EGFRm, 2/3L EGFRm & Anti-Trop2 ADC

OncoAlert

C. Aggarwal

388 views
20:43

Newer Types of Treatment for Lung Cancer: ADCs and Bispecifics

GRACE

L. Bazhenova

336 views
23:50

Targeted Therapies in Lung Cancer 2023: EGFR Targeted Therapies in N…

GRACE

I. Preeshagul

389 views
06:44

ESMO 2023 Insights: "The Impact of PET-CT Brain MRI for Metastasis D…

Insights from 2023 ESMO Annual Meeting

W. Liang

170 views
09:47

Overcoming Resistance in EGFR+ NSCLC

GRACE

A. Desai

213 views